Drug Description
Solution for injection.Clear, colourless aqueous solution.
Presentation
One ml contains 0.44 mg of eribulin (as mesylate)Each 2 ml vial contains 0.88 mg of eribulin (as mesylate)
Indications
monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease (see section 5.1). Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments
Adult Dosage
Halaven should be administered in units specialised in the administration of cytotoxic chemotherapy and only under the supervision of a qualified physician experienced in the appropriate use of cytotoxic medicinal products.
Posology
